Eugene Ahn,MD


Deputy Medical Director of Clinical Research, City of Hope Atlanta, Chicago and Phoenix

Eugene Ahn - Medical Director of Clinical Research & Hematologist/Oncologist

I promise to all of my patients an open, compassionate discussion about all topics related to cancer and together formulation of the best individualized treatment plan.

City of Hope Chicago
2520 Elisha Avenue
Zion, IL 60099
Medical Oncology
Medical school:
University of Miami Miller School of Medicine, Miami, FL
Internal Medicine - University of Utah School of Medicine, Salt Lake City
Infectious Disease, Hematology/Oncology & Microbiology/Immunology, University of Miami Miller School of Medicine
Academic Appointments

Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research, City of Hope


Medical Oncology - American Board of Internal Medicine

Dr. Eugene Ahn, MD, first dreamed of finding a cure for cancer when he was 5 years old. “My father was a hematologist/oncologist, and I always had a strong desire to improve our understanding and treatment of cancer,” says Dr. Ahn, Medical Director of Clinical Research at City of Hope Chicago, which is located between the Chicago and Milwaukee metro areas. He also serves the City of Hope enterprise as Deputy Medical Director of Clinical Research.

Dr. Ahn earned his Bachelor of Arts degree in Biology at Yale University in 1993. He completed his Doctor of Medicine degree at the University of Miami in 1997. His postgraduate training, from 1997 to 2007, included a residency in internal medicine at the University of Utah, fellowships in infectious disease and hematology/oncology at the University Miami, and a National Institutes of Health-funded research fellowship in microbiology/immunology.

From 2007 to 2014, he served as faculty at the same institution, and as Assistant Professor, he was the principal investigator on numerous clinical trials focused on improving the treatment of breast cancer and other diseases. His work is published in renowned journals, including Breast Cancer Research and Treatment, Clinical Breast Cancer and Genomics. In 2016, Chicago Magazine named him to Chicago’s Top Cancer Doctors list for Medical Oncology, and he's been recognized as one of Castle Connolly's Top Doctors® many times, most recently in 2021. In 2017, he was elected by his peers to a three-year term on the board for the Society for Integrative Oncology.

Dr. Ahn is serving a three-year term as Vice President of Communications for the Society of Integrative Oncology and is on the steering committee for the ASCO TAPUR study.

Dr. Ahn recommends complementing conventional treatment plans with patient-preferred mind-body interventions to enhance immunity through innate biological pathways called “psychoneuroimmunology.” Research has shown that mind-body interventions enhance such conventional cancer treatments as surgery, chemotherapy or radiation therapy by improving dose tolerance and ability to complete therapy, quality of life and, in some studies, enhance cure rates.

“Ultimately, I joined City of Hope because they have been delivering for decades this type of integrative care to every patient that is seen here, and I’m excited for the unlimited possibilities we can build here by continuing to offer and further innovate this integrative approach,” says Dr. Ahn.

He also serves as City of Hope Chicago's Medical Director for Clinical Research to enhance the clinical research portfolio at City of Hope. He has particular interest in studying the most active ingredients of an integrative oncology approach.

When he is not at City of Hope, Dr. Ahn enjoys spending time with his wife and two daughters, playing piano and guitar, and exploring the beautiful outdoors.

Patient ratings
Star ratings and comments are only available for medical, radiation and gynecologic oncologists. Gynecologic surgical offerings are not included at this time due to a different survey tool required to evaluate these services. CTCA uses a validated Press Ganey® survey, which captures patient experience feedback for the primary oncology services of chemotherapy and radiation therapy at our comprehensive care and research centers. Following industry best practice, star ratings and comments are only published for physicians with a minimum of 30 completed patient surveys.